Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00141323 · ClinicalTrials.gov registry record · Phase 3
Postmenopausal Evaluation and Risk-reduction With Lasofoxifene (PEARL)
A Phase 3 study, sponsored by Ligand Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 8,556
- Enrollment target
NCT00141323: Completed Phase 3 study, sponsored by Ligand Pharmaceuticals.
NCT00141323 is a Phase 3 study that has completed, run by Ligand Pharmaceuticals. The registered enrollment target is 8,556 participants, above the 771-participant average among 15,282 other Phase 3 trials with a reported enrollment target (1010% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00141323, a Phase 3 study, has completed, sponsored by Ligand Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 8,556 participants
- Enrollment target
Study Summary
The purpose of the study is to determine the safety and effectiveness of 2 doses of the investigational drug, lasofoxifene, compared to placebo (an inactive substance) in reducing new spinal fractures in women with osteoporosis.
Interventions
- OTHER placebo
- DRUG lasofoxifene
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8,556 participants |
| Start Date | 2001-11 |
| Est. Completion | 2007-12 |
| Phase | Phase 3 |
What the finished NCT00141323 record still lists
NCT00141323 is an interventional study that assigns participants to a tested intervention. Its 8,556 participants enrollment target places it among the larger protocols in the corpus, above the 771-participant average among 15,282 other Phase 3 trials with a reported enrollment target (1010% higher).
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00141323 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00141323 about?
NCT00141323 is a clinical study titled "Postmenopausal Evaluation and Risk-reduction With Lasofoxifene (PEARL)". The purpose of the study is to determine the safety and effectiveness of 2 doses of the investigational drug, lasofoxifene, compared to placebo (an inactive substance) in reducing new spinal fractures in women with osteoporosis.
What is the current status of trial NCT00141323?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 8,556 participants. The study started on 2001-11. Estimated completion is 2007-12.
What interventions are being tested in trial NCT00141323?
The interventions under investigation include: placebo (OTHER), lasofoxifene (DRUG).
Who is sponsoring clinical trial NCT00141323?
This trial is sponsored by Ligand Pharmaceuticals, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00141323's enrollment target sits among peer trials
8,556 32nd of 2000 higher than 1,969 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06098079 · 8,600 participants · Phase 4
Effect of Naltrexone Hydrochloride ER and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on Major Adverse Cardiovascular Events (MACE)
- NCT06058234 · 8,680 participants
Medicare Anti-Aβ mAb Coverage With Evidence Development (CED) Study
- NCT05336877 · 8,744 participants
Aveir VR Coverage With Evidence Development Post-Approval Study
- NCT07185828 · 8,286 participants · NA
Informing Low-acuity Emergency Department Patients of Non-emergent Resources (2)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia